• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cannabis Stock Movers For March 5, 2024

    3/5/24 4:30:05 PM ET
    $CARA
    $CGC
    $NEPT
    $PMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CARA alert in real time by email

    GAINERS:

    • Affinor Growers (OTC:RSSFF) shares closed up 44.80% at $0.04
    • MGC Pharmaceuticals (OTC:MGCLF) shares closed up 20.02% at $0.29
    • Heritage Cannabis Holding (OTC:HERTF) shares closed up 19.39% at $0.01
    • CordovaCann (OTC:LVRLF) shares closed up 15.88% at $0.09
    • Target Group (OTC:CBDY) shares closed up 14.26% at $0.00
    • 1933 Industries (OTC:TGIFF) shares closed up 8.33% at $0.01
    • Rocky Mountain High (OTC:RMHB) shares closed up 6.67% at $0.01
    • Cresco Labs (OTC:CRLBF) shares closed up 4.35% at $1.69
    • iAnthus Capital Hldgs (OTC:ITHUF) shares closed up 4.17% at $0.02
    • Zoned Props (OTC:ZDPY) shares closed up 4.02% at $0.51
    • 22nd Century Group (NASDAQ:XXII) shares closed up 3.75% at $0.17
    • Psychemedics (NASDAQ:PMD) shares closed up 3.55% at $3.21
    • CV Sciences (OTC:CVSI) shares closed up 3.48% at $0.03

    LOSERS:

    • Green Growth Brands (OTC:GGBXF) shares closed down 99.50% at $0.00
    • Item 9 Labs (OTC:INLB) shares closed down 25.00% at $0.00
    • Body and Mind (OTC:BMMJ) shares closed down 22.62% at $0.07
    • Nextleaf Solutions (OTC:OILFF) shares closed down 13.98% at $0.10
    • Maple Leaf Green World (OTC:MGWFF) shares closed down 13.38% at $0.03
    • CNBX Pharmaceuticals (OTC:CNBX) shares closed down 13.10% at $0.01
    • Cara Therapeutics (NASDAQ:CARA) shares closed down 12.97% at $0.87
    • 4Front Ventures (OTC:FFNTF) shares closed down 11.11% at $0.09
    • C21 Investments (OTC:CXXIF) shares closed down 10.86% at $0.36
    • EnWave (OTC:NWVCF) shares closed down 9.65% at $0.21
    • Canopy Gwth (NASDAQ:CGC) shares closed down 4.64% at $2.88
    • Neptune Wellness Solns (NASDAQ:NEPT) shares closed down 4.08% at $0.38
    • CLS Holdings USA (OTC:CLSH) shares closed down 3.85% at $0.05

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $CARA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CARA
    $CGC
    $NEPT
    $PMD

    CompanyDatePrice TargetRatingAnalyst
    Canopy Growth Corporation
    $CGC
    3/27/2026Buy
    Canaccord Genuity
    Canopy Growth Corporation
    $CGC
    11/10/2025Sell → Hold
    The Benchmark Company
    Cara Therapeutics Inc.
    $CARA
    6/13/2024$6.00 → $1.00Buy → Hold
    Stifel
    Cara Therapeutics Inc.
    $CARA
    6/13/2024$10.00 → $1.00Buy → Hold
    Canaccord Genuity
    Cara Therapeutics Inc.
    $CARA
    6/13/2024Buy → Hold
    Needham
    Cara Therapeutics Inc.
    $CARA
    6/13/2024Buy → Neutral
    H.C. Wainwright
    Canopy Growth Corporation
    $CGC
    4/4/2023Underperform → Mkt Perform
    Bernstein
    Cara Therapeutics Inc.
    $CARA
    3/8/2023$13.00 → $6.00Neutral → Underperform
    BofA Securities
    More analyst ratings

    $CARA
    $CGC
    $NEPT
    $PMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Yanofsky Theresa

    4 - Canopy Growth Corp (0001737927) (Issuer)

    4/2/26 4:16:22 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Atkins M Shan

    4 - Canopy Growth Corp (0001737927) (Issuer)

    4/2/26 4:16:02 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Bayern Joseph

    4 - Canopy Growth Corp (0001737927) (Issuer)

    4/2/26 4:15:39 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CARA
    $CGC
    $NEPT
    $PMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    22nd Century Group Expands Reduced Nicotine Platform Through New Testing Services Agreement with North Carolina State University

    MOCKSVILLE, N.C., April 23, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on nicotine reduction and plant biotechnology, today announced corporate updates regarding a new testing services agreement with North Carolina State University aimed at validating tobacco varieties featuring improved leaf quality and increased crop yields with the same low-nicotine content. The initiative builds upon 22nd Century's proprietary reduced nicotine content technology platform, which utilizes advanced plant breeding and biotechnology to reduce nicotine content in tobacco to minimally addictive levels. The Company's reduced nicotine tobacco is the foun

    4/23/26 7:50:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    'There's a Tweed for That': Canopy Growth Announces Tweed Brand Summer Campaign

    New window bags, improved potency, and sharper pricing arrive at retail Victoria Day long weekend Canopy Growth Corporation ("Canopy Growth", "Canopy" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced a refresh of Tweed, one of Canada's most recognizable cannabis brands, alongside a national summer campaign, "There's a Tweed for That." This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260423388138/en/The Tweed summer campaign launches over the Victoria Day long weekend, the traditional kickoff to the Canadian summer, spotlighting Tweed's updated portfolio, including three new flower strains and the popular Quickies pre-ro

    4/23/26 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Advances Reduced Nicotine Product to Target Approximately Half of the ~$82 Billion U.S. Cigarette Market with 100mm VLN® Product Initiative

    Company to Pursue Additional PMTA Submissions, Building on Its Status as the Only Holder of an FDA-Authorized Low Nicotine Combustible Cigarette Branded as VLN® Products Expanded PMTA Portfolio and Licensing Strategy Designed to Address Wider Consumer Preference and Unlock Further Retail Penetration Opportunities MOCKSVILLE, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced an update on the advancement of a 100mm VLN® reduced nicotine content cigarette. The Company's proprietary reduced nicotine technology is designed to serve adult smokers who w

    4/7/26 8:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $CARA
    $CGC
    $NEPT
    $PMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Mongeau Luc bought $49,994 worth of shares (27,469 units at $1.82), increasing direct ownership by 3% to 812,368 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    9/23/25 4:15:11 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Large owner Powell Anderson Capital Partners Llc bought $305,439 worth of shares (159,700 units at $1.91) (SEC Form 4)

    4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

    12/17/24 8:29:49 PM ET
    $PMD
    Medical Specialities
    Health Care

    Large owner Powell Anderson Capital Partners Llc bought $231,849 worth of shares (86,991 units at $2.67) (SEC Form 4)

    4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

    12/12/24 8:41:51 PM ET
    $PMD
    Medical Specialities
    Health Care

    $CARA
    $CGC
    $NEPT
    $PMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

    For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

    12/23/21 9:06:12 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    FDA Approval for KORSUVA issued to CARA THERAPEUTICS INC

    Submission status for CARA THERAPEUTICS INC's drug KORSUVA (ORIG-1) with active ingredient DIFELIKEFALIN has changed to 'Approval' on 08/23/2021. Application Category: NDA, Application Number: 214916, Application Classification: Type 1 - New Molecular Entity

    8/24/21 12:36:58 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    $CGC
    $NEPT
    $PMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Canopy Growth

    Canaccord Genuity initiated coverage of Canopy Growth with a rating of Buy

    3/27/26 8:46:41 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth upgraded by The Benchmark Company

    The Benchmark Company upgraded Canopy Growth from Sell to Hold

    11/10/25 8:33:16 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Cara Therapeutics downgraded by Stifel with a new price target

    Stifel downgraded Cara Therapeutics from Buy to Hold and set a new price target of $1.00 from $6.00 previously

    6/13/24 7:05:24 AM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARA
    $CGC
    $NEPT
    $PMD
    SEC Filings

    View All

    SEC Form EFFECT filed by 22nd Century Group Inc.

    EFFECT - 22nd Century Group, Inc. (0001347858) (Filer)

    4/13/26 12:15:24 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 424B5 filed by 22nd Century Group Inc.

    424B5 - 22nd Century Group, Inc. (0001347858) (Filer)

    4/10/26 4:35:13 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 424B5 filed by 22nd Century Group Inc.

    424B5 - 22nd Century Group, Inc. (0001347858) (Filer)

    4/10/26 4:30:36 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $CARA
    $CGC
    $NEPT
    $PMD
    Financials

    Live finance-specific insights

    View All

    22nd Century Group Reports Fourth Quarter and Full Year 2025 Financial Results

    VLN® Commercial Expansion Drives Continued Shift Toward Higher Margin Proprietary Branded Products Expanding VLN® Store Counts and State Authorizations Increase Availability of Smoking Harm Reduction Products MOCKSVILLE, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced results for the fourth quarter and fiscal year-ended December 31, 2025, and provided an update on recent business highlights. The Company's proprietary low nicotine technology is designed to serve adult smokers who want to change their smoking habits by significantly reduci

    3/26/26 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group Preliminarily Reports Fourth Quarter and Full Year 2025 Financial Results

    Balance sheet strength, ended 2025 with $7.1 million in cash and debt free, supports transition to growth Continued VLN® commercial expansion drives shift toward higher margin proprietary branded products MOCKSVILLE, N.C., Feb. 20, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced select, preliminary and unaudited financial results and operating metrics for the fourth quarter and full year ended December 31, 2025. The company anticipates releasing fourth quarter and full year 2025 earnings on or before March

    2/20/26 4:15:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth to Report Third Quarter Fiscal 2026 Financial Results on February 6, 2026

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED, NASDAQ:CGC) will release its financial results for the third quarter fiscal year 2026 ended December 31, 2025 before financial markets open on February 6, 2026. Following the release of its third quarter fiscal year 2026 financial results, Canopy Growth will host an audio webcast with Luc Mongeau, CEO and Tom Stewart, CFO on February 6, 2026 at 10 AM Eastern Time (ET). Webcast Information A live audio webcast will be available at: https://onlinexperiences.com/Launch/QReg/ShowUUID=45C34153-5530-4D6A-A742-BC34AD2534FA Replay Information A replay will be accessible by webcast until 11:59 PM ET on May 7, 2026 at:

    1/23/26 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CARA
    $CGC
    $NEPT
    $PMD
    Leadership Updates

    Live Leadership Updates

    View All

    'There's a Tweed for That': Canopy Growth Announces Tweed Brand Summer Campaign

    New window bags, improved potency, and sharper pricing arrive at retail Victoria Day long weekend Canopy Growth Corporation ("Canopy Growth", "Canopy" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced a refresh of Tweed, one of Canada's most recognizable cannabis brands, alongside a national summer campaign, "There's a Tweed for That." This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260423388138/en/The Tweed summer campaign launches over the Victoria Day long weekend, the traditional kickoff to the Canadian summer, spotlighting Tweed's updated portfolio, including three new flower strains and the popular Quickies pre-ro

    4/23/26 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Announces Storz & Bickel Executive Transition

    David Männer appointed Managing Director Jürgen Bickel, who co-founded and built Storz & Bickel into a global premium vaporization technology leader, passes the torch following 25 years of transformational leadership Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced the appointment of David Männer as Managing Director of Storz & Bickel, a subsidiary of Canopy Growth, effective April 1, 2026. Mr. Männer succeeds Jürgen Bickel, Storz & Bickel's Co-founder, who has decided to transition out of his role. Founded in 2001, Storz & Bickel has grown into a global leader in vaporization technology. Today, it sets the standard for innovation, p

    3/27/26 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Completes Acquisition of MTL Cannabis Creating Canada's Leading Medical Cannabis Business By Revenue

    This news release constitutes a "designated news release" for the purposes of Canopy Growth's prospectus supplement dated August 29, 2025 to its short form base shelf prospectus dated June 5, 2024 All financial amounts in this press release are expressed in Canadian dollars. Strengthens Canopy Growth's core Canadian platform, providing additional high-quality flower to support international growth Expected run-rate synergies of approximately $10 million within 18 months Canopy Growth's leadership team and operational depth strengthened through addition of MTL management team members Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) and MTL Cannab

    3/16/26 7:41:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CARA
    $CGC
    $NEPT
    $PMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Psychemedics Corporation

    SC 13D/A - PSYCHEMEDICS CORP (0000806517) (Subject)

    12/12/24 5:15:40 PM ET
    $PMD
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psychemedics Corporation

    SC 13G/A - PSYCHEMEDICS CORP (0000806517) (Subject)

    12/6/24 9:18:20 PM ET
    $PMD
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13D/A filed by Psychemedics Corporation

    SC 13D/A - PSYCHEMEDICS CORP (0000806517) (Subject)

    12/5/24 6:04:48 PM ET
    $PMD
    Medical Specialities
    Health Care